Letters
FDA on rosiglitazone
More on advisory committee decision
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4868 (Published 07 September 2010) Cite this as: BMJ 2010;341:c4868
- David J Graham, medical officer1,
- Kate Gelperin, medical officer1
- 1Office of Surveillance and Epidemiology, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA
- david.graham1{at}fda.hhs.gov
Your readers may be interested in additional background concerning the recent US Food and Drug Administration (FDA) advisory committee meeting on rosiglitazone.1 In July 2007 a joint meeting of two FDA advisory committees voted 20-3 that rosiglitazone increased the risk of acute myocardial ischaemia and 22-1 that rosiglitazone remain on the market, without ever describing the drug’s benefits or explaining how they exceeded its cardiovascular risks. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.